Tretinoin

Generic Name
Tretinoin
Brand Names
Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
Drug Type
Small Molecule
Chemical Formula
C20H28O2
CAS Number
302-79-4
Unique Ingredient Identifier
5688UTC01R
Background

Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...

Indication

Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...

Associated Conditions
Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

First Posted Date
2017-01-25
Last Posted Date
2020-03-20
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
80
Registration Number
NCT03031249
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

First Posted Date
2016-10-24
Last Posted Date
2024-05-08
Lead Sponsor
University Hospital Regensburg
Target Recruit Count
10
Registration Number
NCT02942758
Locations
🇩🇪

University Hospital Regensburg, Regensburg, Germany

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

First Posted Date
2016-09-14
Last Posted Date
2021-09-08
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
110
Registration Number
NCT02899169
Locations
🇨🇳

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

First Posted Date
2016-07-25
Last Posted Date
2023-07-11
Lead Sponsor
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Target Recruit Count
45
Registration Number
NCT02842827
Locations
🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

First Posted Date
2016-03-24
Last Posted Date
2018-10-18
Lead Sponsor
Michael Luebbert
Target Recruit Count
60
Registration Number
NCT02717884
Locations
🇩🇪

Universitätsklinikum Freiburg, Medical School Freiburg, Freiburg, Germany

🇩🇪

Universitätsklinikum Tübingen, Medical School Tuebingen, Tübingen, Tuebingen, Germany

🇩🇪

Universitätsklinikum Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany

and more 3 locations

Addition of a Topical Steroid to a Topical Retinoid in Acne Patients

Not Applicable
Conditions
Acne
Interventions
Drug: Triamcinolone
Drug: Tretinoin
Drug: Emollient
First Posted Date
2016-03-10
Last Posted Date
2016-03-10
Lead Sponsor
Carilion Clinic
Target Recruit Count
20
Registration Number
NCT02704507

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

First Posted Date
2016-02-23
Last Posted Date
2023-11-02
Lead Sponsor
Technische Universität Dresden
Target Recruit Count
280
Registration Number
NCT02688140
Locations
🇩🇪

OSHO study group, Multiple Locations, Germany

🇩🇪

SAL study group, Multiple Locations, Germany

🇳🇱

HOVON study group, Multiple Locations, Netherlands

and more 5 locations

NB2013-HR German (GPOH) / Dutch (DCOG) Trial

First Posted Date
2015-12-29
Last Posted Date
2022-11-04
Lead Sponsor
University of Cologne
Target Recruit Count
3
Registration Number
NCT02641782
Locations
🇩🇪

University of Cologne, Cologne, Germany

De Novo Lipogenesis of Sebaceous Glands in Acne

Early Phase 1
Completed
Conditions
Acne Vulgaris
Interventions
Drug: Isotretinoin
Drug: Tretinoin
First Posted Date
2015-12-03
Last Posted Date
2021-08-05
Lead Sponsor
University of California, Davis
Target Recruit Count
32
Registration Number
NCT02620813
Locations
🇺🇸

Dermatology Research Area, Davis, California, United States

🇺🇸

UC Davis Department of Dermatology, Sacramento, California, United States

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
Drug: Ipilimumab
Drug: VESANOID
First Posted Date
2015-03-31
Last Posted Date
2023-09-21
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
10
Registration Number
NCT02403778
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy